Mark to market on Ranbaxy

Mint 2018-02-08

Views 0

Ranbaxy Laboratories got approval to launch Lipitor in the December quarter. But Mint?s Ravi Ananthanarayanan says that while consolidated revenues rose, it has disappointed investors by paying more than expected to Teva Pharmaceutical.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
Mark to Market on FIIs and the markets
play
01:06

Mark to Market on FIIs and the markets
Mark To Market on HDFC
play
01:09

Mark To Market on HDFC
Mark to Market on Jyothi Laboratories
play
01:30

Mark to Market on Jyothi Laboratories
Mark to Market on Coal India
play
01:36

Mark to Market on Coal India
Mark to Market on Titan Industries
play
01:32

Mark to Market on Titan Industries
Mark to Market on Idea Cellular
play
00:50

Mark to Market on Idea Cellular
Mark to Market on Titan Industries
play
01:40

Mark to Market on Titan Industries
Mark to Market on TCS
play
02:08

Mark to Market on TCS
Mark to Market on Commodities
play
01:22

Mark to Market on Commodities
Mark to Market| Axis Bank Q3 results
play
01:33

Mark to Market| Axis Bank Q3 results
Mark to Market on bank earnings
play
01:23

Mark to Market on bank earnings
Mark to Market: Is DFCL worth investing in?
play
01:58

Mark to Market: Is DFCL worth investing in?